Contraindications: Dogs with known hypersensitivity to meloxicam should not receive Meloxidyl Oral Suspension. Do
not use Meloxidyl Oral Suspension in cats. Acute renal failure and death have been associated with the use of
meloxicam in cats.
Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case
of accidental ingestion by humans. For oral use in dogs only.
As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID
therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is
recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs
of potential drug toxicity and be given a client information sheet about Meloxidyl Oral Suspension.
Precautions: The safe use of Meloxidyl Oral Suspension in dogs younger than 6 months of age, dogs used for
breeding, or in pregnant or lactating dogs has not been evaluated. Meloxicam Oral Suspension is not recommended
for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. As a class,
cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to
drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from
one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are
those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic
dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may
inhibit the prostaglandins that maintain normal homeostatic function. Such antiprostaglandin effects may result in
clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed.
Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with
other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is
needed after administration of the total daily dose of Meloxidyl Oral Suspension, a non-NSAID or non-corticosteroid
class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate
washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of
concomitantly protein-bound drugs with Meloxidyl Oral Suspension has not been studied in dogs. Commonly used
protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs
that may inhibit metabolism of Meloxidyl Oral Suspension has not been evaluated. Drug compatibility should be
monitored in patients requiring adjunctive therapy.
Adverse Reactions: Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities
(vomiting, soft stools, diarrhea, and inappetance) were the most common adverse reactions associated with the
administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced
them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study.
In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions